Systemic RNA Delivery to Tumors
全身性 RNA 递送至肿瘤
基本信息
- 批准号:10297216
- 负责人:
- 金额:$ 58.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-21 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAftercareAgonistAmerican Cancer SocietyAnimal ModelApoptosisAutophagocytosisBiodistributionBiological MarkersBlood CirculationCancer PatientCellsCessation of lifeChargeCombined Modality TherapyCytotoxic T-LymphocytesDevelopmentDiseaseDrug KineticsEconomic BurdenEngineeringExcretory functionFaceFormulationFoundationsFundingGene ExpressionGenerationsGenetically Engineered MouseGoalsGrowthHMGB1 ProteinHybridsImmuneImmune checkpoint inhibitorImmune responseImmunocompetentImmunologic MemoryIn VitroIndividualInjectionsKidneyLightLipidsMalignant NeoplasmsMalignant neoplasm of prostateMediatingMessenger RNAModalityModelingMolecularMolecular WeightMusMutateMutationNatureNeoplasm MetastasisNon-Small-Cell Lung CarcinomaOncogenesPTEN genePatternPharmaceutical PreparationsPhenotypePolymersPredispositionProstate Cancer therapyRNARNA deliveryRegulatory T-LymphocyteResearch Project GrantsRoleSafetySeriesSmall Interfering RNASolid NeoplasmSurfaceSystemT cell responseTLR9 geneTP53 geneTechnologyTestingTherapeuticTherapeutic EffectTransfectionTransgenic ModelTranslationsTumor Cell LineTumor ImmunityTumor Suppressor ProteinsUnited StatesValidationWorkanti-PD1 antibodiesanti-PD1 therapyanti-tumor immune responsebasecancer cellcancer therapycancer typeclinical developmentcytokinecytotoxiccytotoxicityimmune checkpointimmune checkpoint blockadeimmunogenic cell deathimprovedin vivometastasis preventionnanomedicinenanoparticlenanoparticle deliverynanotherapyneoplastic cellnovelnovel strategiesnovel therapeuticsnucleaseprogrammed cell death protein 1prostate cancer cellprostate cancer modelprotein expressionrestorationsocialsubcutaneoustumortumor growthtumor microenvironmenttumor-immune system interactionsuptake
项目摘要
ABSTRACT
The use of RNA technologies to specifically target genetic alterations in tumor cells has shown great potential of
becoming a novel therapy modality for cancer treatment. Nevertheless, systemic delivery of RNA agents such
as messenger RNA (mRNA) to tumor cells in vivo commonly faces multiple barriers, including low stability, rapid
elimination by renal excretion, insufficient cellular uptake, poor endosomal escape, and transient activities. Our
long-term objective is to develop robust nanoparticle (NP) platforms for effective and safe RNA delivery to solid
tumors, and along with cancer target validation in vivo, to eventually transition the RNA nanomedicines into
clinical development. In the last funding cycle, a lipid-polymer hybrid RNA NP system has been engineered with
favorable features, such as small size, high RNA encapsulation, efficient cytosolic translocation, and relatively
long blood circulation. We have also pioneered the application of these hybrid NPs for mRNA delivery to restore
tumor suppressors (e.g., PTEN) in different cancer types including prostate cancer (PCa) and non-small cell lung
cancer, which represents a novel approach to cancer treatment that is independent of oncogene antagonism. In
our latest work, we further reveal that PTEN restoration in PTEN-null/mutated murine tumor cell lines can induce
immunogenic cell death (ICD). Preliminary in vivo studies show that PTEN mRNA NP treatment triggers cytotoxic
T cell responses, modulates the immunosuppressive tumor microenvironment, and improves the responses of
immune checkpoint blockade therapy. In this renewal application, we propose to i) address the unique challenge
of transient bioactivity in mRNA delivery by developing a new generation of hybrid mRNA NPs, and ii) apply the
new hybrid mRNA NPs to explore PTEN restoration-induced ICD and evaluate the anti-tumor efficacy of PTEN
restoration along with immune checkpoint blockade. Specifically, the three Aims underlying the proposal are: 1)
To optimize the new generation of hybrid NPs and study the NP-mediated long duration of mRNA bioactivity with
the goal of achieving prolonged PTEN expression in PCa tumors using as infrequent injections as possible; 2)
To apply the optimized mRNA NPs to investigate the mechanisms underlying PTEN-mediated ICD and anti-
tumor immune responses and to evaluate the therapeutic effect and safety in subcutaneously grafted, orthotopic,
and transgenic models of PCa; and 3) To expand the new hybrid mRNA NPs to systemic co-delivery of PTEN
mRNA and CpG oligodeoxynucleotide (a toll-like receptor-9 agonist) for stronger ICD and to test the co-delivery
NPs for PCa treatment together with immune checkpoint inhibitors. We expect that successful completion of this
project will lead to development of a novel synthetic mRNA nanotherapy that could benefit cancer patients with
loss/mutation of PTEN. Moreover, this NP delivery strategy could be readily expanded to other tumor suppressor-
encoding mRNAs for various malignancies.
抽象的
利用 RNA 技术特异性靶向肿瘤细胞的基因改变已显示出巨大的潜力
成为癌症治疗的新型治疗方式。然而,RNA 药物的全身递送,例如
作为体内肿瘤细胞的信使RNA(mRNA)通常面临多重障碍,包括稳定性低、快速
通过肾排泄消除、细胞摄取不足、内体逃逸不良和短暂活性。我们的
长期目标是开发强大的纳米颗粒 (NP) 平台,以有效、安全地将 RNA 递送至固体
肿瘤,以及体内癌症靶点验证,最终将 RNA 纳米药物转化为
临床开发。在上一个资助周期中,脂质聚合物混合 RNA NP 系统已被设计为
有利的特征,例如小尺寸、高RNA封装、有效的胞质易位以及相对
血液循环时间长。我们还率先应用这些混合纳米颗粒进行 mRNA 递送,以恢复
不同癌症类型(包括前列腺癌 (PCa) 和非小细胞肺癌)中的肿瘤抑制因子(例如 PTEN)
癌症,它代表了一种独立于癌基因拮抗作用的癌症治疗新方法。在
我们的最新工作,我们进一步揭示了 PTEN 缺失/突变的鼠肿瘤细胞系中 PTEN 的恢复可以诱导
免疫原性细胞死亡(ICD)。初步体内研究表明 PTEN mRNA NP 治疗会引发细胞毒性
T 细胞反应,调节免疫抑制肿瘤微环境,并提高
免疫检查点阻断疗法。在此续签申请中,我们建议 i) 解决独特的挑战
通过开发新一代混合 mRNA NP 来提高 mRNA 递送中的瞬时生物活性,并且 ii) 应用
新的杂交mRNA NPs探索PTEN恢复诱导的ICD并评估PTEN的抗肿瘤功效
恢复以及免疫检查点封锁。具体来说,该提案的三个目标是:1)
优化新一代混合纳米粒子并研究纳米粒子介导的长持续时间的 mRNA 生物活性
使用尽可能不频繁的注射来实现延长 PCa 肿瘤中 PTEN 表达的目标; 2)
应用优化的 mRNA NP 来研究 PTEN 介导的 ICD 和抗-
肿瘤免疫反应并评估皮下移植、原位、
PCa 转基因模型; 3) 将新的混合 mRNA NP 扩展到 PTEN 的系统共递送
mRNA 和 CpG 寡脱氧核苷酸(Toll 样受体 9 激动剂)用于更强的 ICD 并测试共同递送
与免疫检查点抑制剂一起用于 PCa 治疗的 NP。我们期待本次活动的顺利完成
该项目将开发一种新型合成 mRNA 纳米疗法,使癌症患者受益
PTEN 丢失/突变。此外,这种 NP 递送策略可以很容易地扩展到其他肿瘤抑制-
编码多种恶性肿瘤的 mRNA。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jinjun Shi其他文献
Jinjun Shi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jinjun Shi', 18)}}的其他基金
A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy
新型脂质纳米颗粒技术实现长效 mRNA 治疗
- 批准号:
10669826 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance
长效 RNAi 治疗动脉粥样硬化和胰岛素抵抗
- 批准号:
10424582 - 财政年份:2021
- 资助金额:
$ 58.56万 - 项目类别:
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance
长效 RNAi 治疗动脉粥样硬化和胰岛素抵抗
- 批准号:
10631236 - 财政年份:2021
- 资助金额:
$ 58.56万 - 项目类别:
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance
长效 RNAi 治疗动脉粥样硬化和胰岛素抵抗
- 批准号:
10277786 - 财政年份:2021
- 资助金额:
$ 58.56万 - 项目类别:
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
纳米粒子联合递送 RNAi 和化疗治疗多重耐药癌症
- 批准号:
8689250 - 财政年份:2013
- 资助金额:
$ 58.56万 - 项目类别:
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
纳米粒子联合递送 RNAi 和化疗治疗多重耐药癌症
- 批准号:
8707222 - 财政年份:2013
- 资助金额:
$ 58.56万 - 项目类别:
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
纳米粒子联合递送 RNAi 和化疗治疗多重耐药癌症
- 批准号:
8916630 - 财政年份:2013
- 资助金额:
$ 58.56万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 58.56万 - 项目类别:














{{item.name}}会员




